Lansoprazole versus omeprazole: Influence on meal-stimulated gastric acid secretion

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 2, 1997, Pages 359-364

  Dammann, H G ^a   Fuchs, W ^b   Richter, G ^b   Burkhardt, F ^a   Wolf, N ^a   Walter, Th A ^a  

^a Scientific Institute   (Germany)

^b Takeda Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PLACEBO;

ADULT; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION; VOLUNTEER;

EID: 0030932707     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.157332000.x     Document Type: Article

References (25)

1. Huber R, Kohl B, Sachs G, Senn-Bilfinger J, Simon WA, Sturm E. Review article: the continuing development of proton pump inhibitors with particular reference to pantoprazole. Aliment Pharmacol Ther 1995, 9: 363-78.
2. +)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J Pharmacol Exp Ther 1989, 248(2): 799-805.
3. + ATPase. Ann Rev Pharmacol Toxicol 1995, 35: 277-305.
4. Simon A, Besancon M, Shin JM, Sachs G. The H, K ATPase sites that react selectively with the benzimidazole class of anti-ulcer drugs. Gastroenterology 1993; 104(4): A192 (Abstract).
5. Tucker GT. The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 1994: 8 (Suppl. 1): 33-8.
6. Lefebvre RA, Flouvat B, Karolac-Tamisier S, et al. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther 1992; 52: 458-63.
7. Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Gastroenterology 1985; 89: 1235-41.
8. Delhotal-Landes B, Flouvat B, Duchier J, et al. Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol 1993; 45: 367-71.
9. Gerloff J, Mignot A, Barth H, Heintze K. Pharmacokinetics and absolute bioavailability of lansoprazole. Eur J Clin Pharmacol 1996; 50: 293-7.
10. Andersson T, Andén K, Cederberg C, et al. Pharmacokinetics and bioavailability of omeprazole after single and repeated administration in healthy subjects. Br J Clin Pharmacol 1990; 29: 557-63.
11. Andersson T, Regårdh C-G. Pharmokokinetics of omeprazole and metabolites following single intravenous and oral doses of 40 and 80 mg. Drug Invest 1990; 2: 255-63.
12. Becker HD. Methodischer Fortschritt in der Funktionsdiagnostik des Magens: Magensekretionsanalyse, intragastrale Titration, endokrine Provokationstests. [Methodological advances in functional diagnostics of the stomach: analysis of gastric secretion, intragastric titration, endocrine provocation test.] Zeitschrift für Gastroenterologie 1978, 3(16): 118-25.
13. Fordtran JS, Walsh JH. Gastric acid secretion rate and buffer content of the stomach after eating. J Clin Invest 1973, 52: 645-57.
14. 2-receptor antagonist on food-stimulated acid secretion, serum gastrin and gastric emptying in patients with duodenal ulcers. Comparison with an anticholinergic drug. J Clin Invest 1975; 55: 536-42
15. Johns B, Kenward MG. Design and Analysis of Cross-Over Trials. London: Chapman & Hall, 1989.
16. Hogan DL, Koss MA, Feitelberg S, et al. Single and repetitive administration of lansoprazole : effects on gastric acid secretion, pharmacokinetics and serum gastrin in old vs. young subjects. Gastroenterology 1991; 100: A84 (Abstract).
17. Muller P, Dammann HG, Leucht U, Simon B. Human gastric acid secretion following repeated doses of AG-1749. Aliment Pharmacol Ther 1989; 3: 193-8.
18. Olbe L, Lind T, Cederberg C, Ekenved G. Effect of Omeprazole on Gastric Acid Secretion in Man. In: Borg KO, Olbe L, Rune SJ, Walan A, Eds. Proceedings of the First International Symposium on Omeprazole. Oxford, UK: The Alden Press, 1986: 105-7.
19. Tateno M, Nakamura N. Phase I study of lansoprazole (AG-1749) antiulcer agent. Capsule form. Rinsho Iyaku 1991, 7: 51-62.
20. Barradell LB, Faulds D, McTavish D. Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44(2): 225-50.
21. Tolman KG, Sanders SW, Buchi KN. Gastric pH levels after 15 mg and 30 mg Lansoprazole or 20 mg Omeprazole. Gastroenterology 1994, 106(4): A172 (Abstract).
22. Freund H, Bruck L, Axthelm EH. Intragastrale pH-Werte nach Gabe von 1 × 30 mg Lansoprazol oder 2 × 20 mg Omeprazol bei Patienten mit Ulcus duodeni. [Intragastric pH after administration of 1 × 30 mg lansoprazole or 2 × 20 mg omeprazole in patients with duodenal ulcer.] Verdauungskrankheiten 1996; 14(2): 56-9.
23. Seensalu R, Iwarzon M, Janczewska I, et al. Dose-response comparison of Lansoprazole and Omeprazole on 24-hour gastric acidity and plasma gastrin in healthy volunteers. Gastroenterology 1995; 108(4) (Suppl.): A215 (Abstract).
24. Verdú EF, Fraser R, Armstrong D, Blum AL. Lansoprazole and Omeprazole, at therapeutic doses, produce equivalent rises in gastric pH in Helicobacter pylori (Hp) positive subjects. Gastroenterology 1994; 106(4): A205 (Abstract).
25. Garg SK, Chugh Y, Tripathi K, Kumar N, Sharma PL. Comparative bioavailability of two enteric-coated capsules of omeprazole in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1992; 31(2): 96-9.